Navigation Links
Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results from the Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positive clinical profile of the Endeavor(R) drug-eluting coronary stent and bring to nearly 1,300 the number of Endeavor patients who have at least two years of follow-up. Significantly, among those 1,300 Endeavor patients, there have been no reported cases of late stent thrombosis using the independent, pre-specified clinical trial protocol definitions for thrombosis. The results were presented today during the 56th Annual Scientific Session of the American College of Cardiology (ACC) conference in New Orleans.

Those in the 436-patient ENDEAVOR III trial are being followed out to five years. The clinical data reported at ACC as part of the study design indicate that the Endeavor stent continues to exhibit an excellent safety profile while delivering sustained efficacy and a low need for repeat procedures that is consistent with the overall Endeavor clinical program. At two years, the rate of Major Adverse Cardiac Events - a composite safety measure of death, repeat procedures and myocardial infarction (MI) - was reported to be 9.3% for Endeavor and 11.6% for the Cypher stent also studied in the ENDEAVOR III trial (p = 0.47). There was no statistically significant difference in the need for repeat procedures, or Target Lesion Revascularization (7.0% and 4.5% for Endeavor and Cypher, respectively, p = 0.50), or all-cause mortality (1.6% for Endeavor and 4.5% for Cypher, p = 0.14). However, fewer patients experienced heart attacks (MI) when treated with the Endeavor stent (0.6% vs. 3.6% for Cypher, p = 0.04) and the combined rate of heart attack and death also was statistically significantly lower among patients randomized to the Endeavor stent (2.2% vs. 7.1% for Cypher, p = 0.013).

Confidence in Endeavor safety

Worldwide, Medtronic has approximately 2,100 Endeavor patients enr
'"/>




Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), the ... for a 2015 Connected World magazine Connected ... System (mPERS), that can be used anywhere, anytime. The ... In nominating MedScope, Landon Garner ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Denali Concrete Management Inc. (OTCBB: DCMG) announced today ... acquisition of Denali by Can-Fite BioPharma Ltd. (TASE: CFBI) ... outstanding shares of EyeFite Ltd., a private company incorporated ... exclusive license over CF101 for ophthalmic indications. Concurrently, Denali ...
... 22, 2011 Par Pharmaceutical Companies, Inc. (NYSE: ... approved the promotions of Thomas J. Haughey to the role ... Chief Operating Officer of the Company and its subsidiaries, effective ... LePore who will retain his title of Chairman of the ...
Cached Medicine Technology:Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer 2
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... patients with coronary artery disease were almost three times ... interventional treatment to arterial plaque than their White European ... IJCP, the International Journal of Clinical Practice . ... emergency and require urgent treatment. Researchers carried out ...
... in sexual activity, the more likely they are to ... to new research presented in Boston at The Gerontological ... This finding is based on the 2004� General Social ... representative sample of non-institutionalized English and Spanish-speaking person 18 ...
... FRIDAY, Nov. 18 (HealthDay News) -- New research suggests that ... communicating via email or instant messages rather than when they ... What,s new is that we lie even more online," said ... at the University of Massachusetts-Amherst. In the study, the ...
... - IBM,s Watson computing system broke new ground earlier this ... Jeopardy! game show. Now, The Scripps Research Institute is hoping ... health with part of the prize money from that tournament: ... the public,s help. To that end, Scripps Research ...
... at the University of California, San Diego School of Medicine ... colleagues in Boston and South Korea, say they have identified ... of glioblastoma (GBM), the most common type of malignant brain ... online edition of the journal Cancer Research . ...
... 2011 - The Canadian Diabetes Association is pleased to ... Elsevier to publish the Canadian Journal of Diabetes ... CJD is Canada,s only diabetes-oriented, peer-reviewed, interdisciplinary ... the sharing and enhancement of knowledge to advance the ...
Cached Medicine News:Health News:South Asian patients require 3 times as much repeat angioplasty as white Europeans 2Health News:South Asian patients require 3 times as much repeat angioplasty as white Europeans 3Health News:Study finds sex a significant predictor of happiness among married seniors 2Health News:People May Lie More Often in Emails, Instant Messages 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 2Health News:Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria 3Health News:Old drugs find new target for treating brain tumor 2Health News:Old drugs find new target for treating brain tumor 3
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... supplied on Smart Cards. Insert the card and ... and turns itself off after the programmed time. ... duration of treatments. Simply provide your patient with ... their progress on the next visit.,The initial set ...
... painfree therapy stimulates the spincter and ... contractions and relaxation. By use of ... surgical operations (bladder liftings) may be ... can improve unsatisfying results. DETRUSAM intravesical ...
... ELPHA 4 Conti is a battery operated ... treatment of conditions described below. ELPHA 4 Conti ... In STRESS- and faecal incontinence ELPHA 4 Conti ... that the user can feel which muscles need ...
Medicine Products: